Molekule Group (Molekule Group) Change In Working Capital : $-5.50 Mil (TTM As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Molekule Group Change In Working Capital?

Molekule Group's change in working capital for the quarter that ended in Jun. 2023 was $0.19 Mil.

Molekule Group's change in working capital for the fiscal year that ended in Dec. 2022 was $2.07 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Molekule Group Change In Working Capital Historical Data

The historical data trend for Molekule Group's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Molekule Group Change In Working Capital Chart

Molekule Group Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Change In Working Capital

0.06

0.19

-0.82

2.07

Molekule Group Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Change In Working Capital	Get a 7-Day Free Trial									0.09	1.29	0.55	-7.52	0.19

Molekule Group Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.50 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Molekule Group Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Molekule Group's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Molekule Group (Molekule Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Industrials » Industrial Products » Molekule Group Inc (OTCPK:MKULQ) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

10455 Riverside Drive, Palm Beach Gardens, FL, USA, 33410

Website

https://www.molekule.com

Molekule Group Inc is an interior space air purification technology company with an immediate objective of initiating full-scale commercialization of its high-performance interior air sterilization and disinfection products for the eradication of coronavirus and other harmful airborne pathogens. The Company was established to develop technology-driven, medical-grade air purification solutions for hospitals and other healthcare settings. Its air hygiene product, Purgo, is an FD medical device that provides continuous air filtration, sanitization, and supplemental ventilation solutions with technology that can be applied in any indoor space including in hospitals, offices, and even in elevators.

Executives

Ritankar Pal	officer: Chief Operating Officer	10455 RIVERSIDE DR., PALM BEACH GARDENS FL 33410
Jonathan Harris	officer: Chief Commercial Officer	3000 CLEARVIEW WAY, SAN MATEO CA 94402
Bradley A Feld	director	C/O FOUNDRY GROUP, 645 WALNUT ST., BOULDER CO 80302
Ryan A Mcintyre	10 percent owner
Seth Levine	10 percent owner	1050 WALNUT STREET, SUITE 210, BOULDER CO 80302
Fg Next Gp, Llc	10 percent owner	1050 WALNUT STREET, SUITE 210, BOULDER CO 80302
Foundry Group Next, L.p.	10 percent owner	C/O FOUNDRY GROUP, 1050 WALNUT STREET, SUITE 219, BOULDER CO 80302
Ward Jr Stephen M	director	C/O CARPENTER TECHNOLOGY CORP, PO BOX 14662, READING PA 19612
Timothy J Scannell	director	2825 AIRVIEW BOULEVARD, KALAMAZOO MI 49002
Heather Floyd	director	1300 CORPORATE CENTER WAY, WELLINGTON FL 33414
Thomas P Mccaffrey	director	1300 CORPORATE CENTER WAY, WELLINGTON FL 33414
Lewis C Pell	10 percent owner	C/O VISION SCIENCES INC, 6 STRATHMORE RD, NATICK MA 01760
Michael F Senft	director	1300 CORPORATE CENTER WAY, WELLINGTON FL 33414
Jason Dibona	officer: Chief Executive Officer	10455 RIVERSIDE DRIVE, PALM BEACH GARDEN FL 33410
David Helfet	director	10455 RIVERSIDE DRIVE, PALM BEACH GARDENS FL 33410